TY  - JOUR
T1  - Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: A sham-controlled randomized trial
AU  - George MS, Lisanby SH, Avery D, et al
Y1  - 2010/05/01
N1  - 10.1001/archgenpsychiatry.2010.46
JO  - Archives of General Psychiatry
SP  - 507
EP  - 516
VL  - 67
IS  - 5
N2  - Context 
    Daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) has been studied as a potential treatment for depression, but previous work had mixed outcomes and did not adequately mask sham conditions.Objective 
    To test whether daily left prefrontal rTMS safely and effectively treats major depressive disorder.Design 
    Prospective, multisite, randomized, active sham-controlled (1:1 randomization), duration-adaptive design with 3 weeks of daily weekday treatment (fixed-dose phase) followed by continued blinded treatment for up to another 3 weeks in improvers.Setting 
    Four US university hospital clinics.Patients 
    Approximately 860 outpatients were screened, yielding 199 antidepressant drug–free patients with unipolar nonpsychotic major depressive disorder.Intervention 
    We delivered rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil. Sham rTMS used a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.Main Outcome Measure 
    In the intention-to-treat sample (n = 190), remission rates were compared for the 2 treatment arms using logistic regression and controlling for site, treatment resistance, age, and duration of the current depressive episode.Results 
    Patients, treaters, and raters were effectively masked. Minimal adverse effects did not differ by treatment arm, with an 88% retention rate (90% sham and 86% active). Primary efficacy analysis revealed a significant effect of treatment on the proportion of remitters (14.1% active rTMS and 5.1% sham) (P = .02). The odds of attaining remission were 4.2 times greater with active rTMS than with sham (95% confidence interval, 1.32-13.24). The number needed to treat was 12. Most remitters had low antidepressant treatment resistance. Almost 30% of patients remitted in the open-label follow-up (30.2% originally active and 29.6% sham).Conclusion 
    Daily left prefrontal rTMS as monotherapy produced statistically significant and clinically meaningful antidepressant therapeutic effects greater than sham.Trial Registration 
    clinicaltrials.gov Identifier: NCT00149838
SN  - 0003-990X
M3  - doi: 10.1001/archgenpsychiatry.2010.46
UR  - http://dx.doi.org/10.1001/archgenpsychiatry.2010.46
ER  -